257 related articles for article (PubMed ID: 35284778)
1. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
3. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K
Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).
Jiménez-Yuste V; Peyvandi F; Klamroth R; Castaman G; Shanmukhaiah C; Rangarajan S; García Chavez J; Martinez R; Kenet G; Alzahrani H; Robson S; Schmitt C; Kiialainen A; Meier O; Ozelo M
Res Pract Thromb Haemost; 2022 Nov; 6(8):e12837. PubMed ID: 36397934
[TBL] [Abstract][Full Text] [Related]
7. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies.
Mahlangu J; Jiménez-Yuste V; Ventriglia G; Niggli M; Barlera S; Hermans C; Lehle M; Chowdary P; Jew L; Windyga J; Frenzel L; Schmitt C; Castaman G; Pipe SW
Res Pract Thromb Haemost; 2024 Feb; 8(2):102364. PubMed ID: 38559572
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
[No Abstract] [Full Text] [Related]
11. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
12. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
[TBL] [Abstract][Full Text] [Related]
14. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
15. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.
Pipe SW; Trzaskoma B; Minhas M; Lehle M; Ko RH; Gao L; Mahlangu J; Kempton CL; Kessler CM; Kruse-Jarres R
Res Pract Thromb Haemost; 2023 Feb; 7(2):100077. PubMed ID: 36908770
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.
Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR
EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515
[TBL] [Abstract][Full Text] [Related]
18. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.
Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V
TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041
[No Abstract] [Full Text] [Related]
19. Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Callaghan MU; Asikanius E; Lehle M; Oldenburg J; Mahlangu J; Uguen M; Chebon S; Kruse-Jarres R; Jiménez-Yuste V; Shima M; Trask P; Kempton CL; Kessler CM; Levy GG; Peyvandi F
Res Pract Thromb Haemost; 2022 Aug; 6(6):e12782. PubMed ID: 36171959
[TBL] [Abstract][Full Text] [Related]
20. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis.
Muniz RL; Camelo RM; Araújo MS; Barbosa MM; Guerra AA; Acurcio FA; Alvares-Teodoro J
Expert Rev Hematol; 2023; 16(12):1087-1097. PubMed ID: 38066708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
